Whole-body physiology-based pharmacokinetics of caspofungin for general patients, intensive care unit patients and hepatic insufficiency patients

[1]  Qianting Yang,et al.  Pharmacokinetic/pharmacodynamic adequacy of echinocandins against Candida spp. in intensive care unit patients and general patient populations. , 2016, International journal of antimicrobial agents.

[2]  G. Hempel,et al.  Physiology-Based Pharmacokinetics of Caspofungin for Adults and Paediatrics , 2015, Pharmaceutical Research.

[3]  P. Pickkers,et al.  Impact of special patient populations on the pharmacokinetics of echinocandins , 2015, Expert review of anti-infective therapy.

[4]  J. Rello,et al.  Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study , 2015, Critical Care.

[5]  M. Danhof,et al.  Drug disposition in obesity: toward evidence-based dosing. , 2015, Annual review of pharmacology and toxicology.

[6]  D. D. de Lange,et al.  Pharmacokinetics of caspofungin in ICU patients. , 2014, The Journal of antimicrobial chemotherapy.

[7]  C. Seger,et al.  Pharmacokinetics of Caspofungin in Critically Ill Patients on Continuous Renal Replacement Therapy , 2013, Antimicrobial Agents and Chemotherapy.

[8]  Mirjam N Trame,et al.  Population Pharmacokinetics of Escalating Doses of Caspofungin in a Phase II Study of Patients with Invasive Aspergillosis , 2013, Antimicrobial Agents and Chemotherapy.

[9]  C. Knibbe,et al.  Impact of Obesity on Drug Metabolism and Elimination in Adults and Children , 2012, Clinical Pharmacokinetics.

[10]  Brian S. Smith,et al.  Introduction to drug pharmacokinetics in the critically ill patient. , 2012, Chest.

[11]  Kuresh Youdim,et al.  Application of PBPK modelling in drug discovery and development at Pfizer , 2012, Xenobiotica; the fate of foreign compounds in biological systems.

[12]  C. Lanvers-Kaminsky,et al.  Population Pharmacokinetics of Liposomal Amphotericin B and Caspofungin in Allogeneic Hematopoietic Stem Cell Recipients , 2011, Antimicrobial Agents and Chemotherapy.

[13]  J. Vaidyanathan,et al.  Implications of Obesity for Drug Therapy: Limitations and Challenges , 2011, Clinical pharmacology and therapeutics.

[14]  M. Danhof,et al.  A Semiphysiological Population Model for Prediction of the Pharmacokinetics of Drugs under Liver and Renal Disease Conditions , 2011, Drug Metabolism and Disposition.

[15]  M. Ruhnke,et al.  Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis - review of the literature , 2011, European journal of medical research.

[16]  M. Pfaller,et al.  In Vivo Comparison of the Pharmacodynamic Targets for Echinocandin Drugs against Candida Species , 2010, Antimicrobial Agents and Chemotherapy.

[17]  J. Sobel,et al.  Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  C. Vorwerk,et al.  Aqueous Humor Concentrations of Topically Administered Caspofungin in Rabbits , 2008, Ophthalmic Research.

[19]  Walter Schmitt,et al.  Whole body physiologically-based pharmacokinetic models: their use in clinical drug development , 2008 .

[20]  P. Deutsch,et al.  Single‐ and Multiple‐Dose Administration of Caspofungin in Patients With Hepatic Insufficiency: Implications for Safety and Dosing Recommendations , 2007, Journal of clinical pharmacology.

[21]  M. Weigand,et al.  Factors influencing caspofungin plasma concentrations in patients of a surgical intensive care unit. , 2007, The Journal of antimicrobial chemotherapy.

[22]  A. Shad,et al.  Pharmacokinetics, Safety, and Tolerability of Caspofungin in Children and Adolescents , 2005, Antimicrobial Agents and Chemotherapy.

[23]  Thierry Lavé,et al.  An evaluation of the utility of physiologically based models of pharmacokinetics in early drug discovery. , 2005, Journal of pharmaceutical sciences.

[24]  Xin Xu,et al.  HEPATIC UPTAKE OF THE NOVEL ANTIFUNGAL AGENT CASPOFUNGIN , 2005, Drug Metabolism and Disposition.

[25]  A. Sterrett,et al.  Single- and Multiple-Dose Pharmacokinetics of Caspofungin in Healthy Men , 2002, Antimicrobial Agents and Chemotherapy.

[26]  T. Baillie,et al.  Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[27]  J. Rodríguez-Baño,et al.  [Candidemias: multicentre analysis in 16 hospitals in Andalusia (Spain)]. , 2011, Enfermedades infecciosas y microbiologia clinica.

[28]  T. Lavé,et al.  A Novel Strategy for Physiologically Based Predictions of Human Pharmacokinetics , 2006, Clinical pharmacokinetics.

[29]  Walter Schmitt,et al.  Physiology-based pharmacokinetic modeling: ready to be used. , 2004, Drug discovery today. Technologies.